期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Fondaparinux:一个新的选择性Ⅹa因子抑制剂 被引量：1

Fondaparinux: a novel selective factor Xa inhibitor
下载PDF
导出
摘要 fondaparinux是一个化学合成的全新戊聚糖化合物 ,能够有效地预防大型的下肢骨科手术后常见的静脉血栓栓塞。本文就其药效学、药动学、临床应用及其现状等作一综述。 Fondaparinux, a selective factor Xa inhibitor, is a new pentasaccharide obtained by chemical synthesis. It binds selectively with high affinity to antithrombin Ⅲ and specifically catalyses the inactivation of factor Xa. It has been demonstrated that fondaparinux can significantly reduce the incidence of venous thromboembolism and be well tolerated by patients undergoing major orthopaedic surgery. This review focuses on the pharmacodynamics, pharmacokinetics and therapeutic trial of fondaparinux, so as to prevent venous thromboembolism in patients undergoing major orthopaedic surgery.
作者 陆文铨 刘皋林
机构地区 上海长征医院药学部
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第9期624-627,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 因子Xa 血栓栓塞 血栓溶解疗法 药动学 FONDAPARINUX factor Ⅹa thromboembolism thrombolytic therapy pharmacokinetics fondaparinux
分类号 R543 [医药卫生—心血管疾病] R973.2 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1DIUGUID DL.Choosing a parenteral anticoagulant agent[J]. N Engl J Med,2001,345(18):1340-1342.
  • 2PETITOU M, DUCHAUSSOY P, HERBERT JM,et al. The synthetic pentasacchari de fondaparinux: first in the class of antithrombotic agents that selectively in hibit coagulation factor Xa[J].Semin Thromb Hemost,2002 ,28(4):393-402.
  • 3HERBERT JM, HERAULT JP, BERNAT A, et al. Biochemical and pharmacologic al properties of SANORG 34006, a potent and long-acting synthetic pentasacchari de[J]. Blood, 1998, 91(11):4197-4205.
  • 4AHMAD S, JESKE WP, WALENGA JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies[J ]. Clin Appl Thromb Hemost, 1999, 5(4):259-266.
  • 5BAUER KA, HAWKINS DW, PETERS PC, et al. Fondaparin-ux, a syntheti c pent asaccharide: the first in a new class of antithrombotic agents--the selective factor Xa inhibitors[J]. Cardiovasc Drug Rev,2002,20(1):37-52.
  • 6GALLUS AS,COGHLAN DW. Heparin pentasaccharide[J].Curr Opin Hematol, 2002 , 9(5):422-429.
  • 7GEROTZIAFAS GT, BARA L, BLOCH MF, et al. Comparative effects of syn thetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin a nd recombinant hirudin on the generation of factor Ⅶa and prothrombin ac tivatio n after coagulation of hum
  • 8WALENGA JM, JESKE WP, SAMAMA MM,et al. Fondaparinux: a synthetic hepar in pentasaccharide as a new antithrombotic agent[J].Expert Opin Investig Drugs , 2002,11(3):397-407.
  • 9DONAT F, DURET JP, SANTONI A, et al.The pharmacokinetics of fondaparin ux sodium in healthy volunteers[J]. Clin Pharmacokinet, 2002,41 Suppl 2:1-9.
  • 10FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC,et al. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin[J]. Br J Clin Pharmacol, 2002, 54(3):304-308.

同被引文献12

引证文献1

二级引证文献12

中国新药与临床杂志
2004年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部